(PIDCD/EMRO

## Measles and rubella surveillance summary and data analysis of selected performance indicators -EMR, Week 532016

As of December 2016, case-based surveillance with laboratory confirmation of measles and rubella is functional in 22 EMR member states but operating nation wide in 21 countries of the EMR (Somalia is sentinel site surveillance).

| A. Measles reported data January to December 2015 and January to December 2016 |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Reported cases of measles suspects |  | No.cases tested for measles |  | Total Measles cases |  | Measles Laboratory confirmed |  | Measles incidence |  | Total Rubella cases |  |
|  | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 | 2015 | 2016 |
| Afghanistan | 2017 | 1121 | 1973 | 1120 | 1191 | 641 | 1154 | 641 | 36.89 | 19.86 | 60 | 42 |
| Bahrain | 365 | 398 | 365 | 398 | 0 | 0 | 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Djibouti* | 33 |  | 14 |  | 30 |  | 11 |  | 34.68 |  | 0 |  |
| Iran | 6552 | 4482 | 6186 | 4374 | 646 | 83 | 563 | 63 | 8.21 | 1.05 | 45 | 18 |
| Iraq | 1949 | 359 | 1473 | 326 | 1455 | 27 | 1011 | 27 | 43.79 | 0.81 | 1 | 1 |
| Jordan | 91 | 36 | 91 | 36 | 0 | 0 | 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Egypt | 7291 | 2528 | 5381 | 2424 | 5431 | 225 | 3521 | 122 | 60.94 | 2.52 | 53 | 28 |
| Kuwait | 251 | 176 | 244 | 174 | 18 | 8 | 18 | 8 | 4.96 | 2.20 | 0 | 3 |
| Lebanon | 92 | 127 | 53 | 94 | 39 | 44 | 6 | 13 | 9.15 | 7.66 | 0 | 10 |
| Libya | 102 | 48 | 102 | 43 | 87 | 28 | 87 | 28 | 14.97 | 4.82 | 0 | 0 |
| Morocco | 327 | 191 | 323 | 186 | 17 | 4 | 17 | 4 | 0.53 | 0.12 | 6 | 0 |
| Oman | 1468 | 1844 | 1445 | 1817 | 0 | 153 | 0 | 114 | 0.00 | 34.66 | 0 | 7 |
| Pakistan | 1394 | 5871 | 1394 | 5871 | 337 | 2845 | 337 | 2845 | 1.90 | 16.06 | 226 | 645 |
| Palestine | 186 | 192 | 186 | 191 | 0 | 0 | 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Qatar | 337 | 251 | 327 | 246 | 18 | 30 | 18 | 27 | 10.39 | 17.31 | 7 | 20 |
| Saudi Arabia | 1100 | 944 | 1056 | 942 | 219 | 112 | 219 | 112 | 7.72 | 3.95 | 4 | 24 |
| Somalia | 119 | 35 | 87 | 35 | 112 | 29 | 80 | 29 | 12.88 | 3.33 | 1 | 0 |
| Sudan | 6824 | 4533 | 4502 | 3572 | 3585 | 1767 | 1416 | 863 | 87.12 | 42.94 | 1050 | 996 |
| Syria | 678 | 586 | 678 | 586 | 45 | 66 | 45 | 66 | 2.01 | 2.95 | 0 | 1 |
| Tunisia | 238 | 238 | 210 | 212 | 16 | 7 | 11 | 5 | 1.52 | 0.66 | 23 | 19 |
| UAE | 1004 | 835 | 897 | 736 | 337 | 219 | 250 | 137 | 40.78 | 23.92 | 175 | 138 |
| Yemen | 2417 | 3430 | 2010 | 1173 | 468 | 143 | 89 | 97 | 16.82 | 5.14 | 78 | 56 |
| Total EMR | 34835 | 28225 | 28997 | 24556 | 14051 | 6431 | 8853 | 5201 | 22.92 | 10.36 | 1729 | 2008 |

## B. Surveillance performance indicators:

Measles suspected cases tested between January to December 2016 were 24556 cases compared to 28997 between January to December 2015. The target of $80 \%$ of suspected cases tested for measles and rubella was met in 19 countries of the 22 countries reported between January to December 2016, 19 countries met this indicator between January to December 2015.
The indicator of $80 \%$ of measles cases with complete investigation was met in 14 countries between January to December 2016.

## C. Measles Laboratory performance:

The target of $80 \%$ and more of the results reported back within 4 days between January to December 2016 was met in 13 countries of the 22 reported countries.
The target of $80 \%$ and more of the specimens to be received at the lab within 5 days of specimen collection date between January to December 2016 was met in 12 of the 22 reported countries.
The target of $80 \%$ and more of the specimens received at the Lab in good condition between January to December 2016 was met in 21 countries of the 22 reported countries.

## Notes:

*Djibouti did not report for 2016

EMR cumulative indigenous measles/rubella case counts and surveillance indicators
Between 01/01/2016 and 31/12/2016

| Country | Measles case finding report |  |  |  |  |  |  | Rubella case finding report |  |  |  |  |  | Measl <br> es <br> incide <br> nce <br> 1000, <br> 000 <br> $*$ | Rubel <br> la <br> incide <br> nce <br> 11000, <br> 000 <br> $* *$ | Report ing rate *** | Indicators : target $\geq 80 \%$ |  |  |  |  | Last Date reported | Genotypes reported |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total suspecte d cases for M/R | specimen s tested for measles | Measles <br> Lab <br> confirm <br> ed |  | Measles clinically compatib le | $\begin{array}{\|c\|} \hline \text { Total } \\ \text { measle } \end{array}$ s | $\begin{array}{\|l\|} \hline \text { Measles } \\ \text { discarde } \\ \text { d cases } \end{array}$ | specim <br> ens tested for rubella | $\begin{array}{\|c\|} \hline \text { Rubell } \\ \text { a lab } \\ \text { confir } \\ \text { med } \end{array}$ | Rube IIa Epi- Link ed | $\begin{array}{\|c\|} \hline \text { Rube } \\ \text { Ila } \\ \text { clinic } \\ \text { ally } \end{array}$ | $\begin{array}{\|c} \hline \text { Total } \\ \text { Rubell } \\ \mathrm{a} \end{array}$ | $\begin{aligned} & \text { Rubella } \\ & \text { discarde } \\ & \text { d cases } \end{aligned}$ |  |  |  | $\begin{gathered} \hline \text { suspects } \\ \text { tested } \\ \text { for } \\ \text { measles } \\ * * * * \end{gathered}$ | cases with complete investigati on | specimens recieved at the lab within 5days | specime ns with adequat e condition | results reported back within 4days |  |  |
| Afghanistan | 1121 | 1120 | 641 | 0 | 0 | 641 | 480 | 485 | 42 | 0 | 0 | 42 | 443 | 19.86 | 1.30 | 1.36 | 100\% |  | 58\% | 99\% | 40\% | 31/12/2016 |  |
| Bahrain | 398 | 398 | 0 | 0 | 0 | 0 | 398 | 398 | 0 | 0 | 0 | 0 | 398 | 0.00 | 0.00 | 32.23 | 100\% | 100\% | 100\% | 100\% | 99\% | 29/12/2016 | D8, B3 |
| Iran | 4482 | 4374 | 63 | 8 | 12 | 83 | 4399 | 4374 | 15 | 0 | 3 | 18 | 4356 | 1.05 | 0.19 | 5.57 | 98\% | 99\% | 93\% | 100\% | 96\% | 31/12/2016 | B3 |
| Iraq | 359 | 326 | 27 | 0 | 0 | 27 | 332 | 346 | 1 | 0 | 0 | 1 | 345 | 0.81 | 0.03 | 1.00 | 91\% | 76\% | 41\% | 100\% | 89\% | 31/12/2016 |  |
| Jordan | 36 | 36 | 0 | 0 | 0 | 0 | 36 | 36 | 0 | 0 | 0 | 0 | 36 | 0.00 | 0.00 | 0.59 | 100\% | 86\% | 86\% | 100\% | 58\% | 21/09/2016 |  |
| Egypt | 2528 | 2424 | 122 | 60 | 43 | 225 | 2303 | 2422 | 28 | 0 | 0 | 28 | 2394 | 2.52 | 0.31 | 2.55 | 98\% | 86\% | 94\% | 100\% | 93\% | 31/12/2016 |  |
| Kuwait | 176 | 174 | 8 | 0 | 0 | 8 | 168 | 174 | 3 | 0 | 0 | 3 | 171 | 2.20 | 0.83 | 4.54 | 99\% | 97\% | 88\% | 100\% | 9\% | 31/12/2016 |  |
| Lebanon | 127 | 94 | 13 | 0 | 31 | 44 | 83 | 83 | 4 | 0 | 6 | 10 | 73 | 7.66 | 0.70 | 1.38 | 74\% | 97\% | 70\% | 97\% | 96\% | 29/12/2016 | D8 |
| Libya | 48 | 43 | 28 | 0 | 0 | 28 | 20 | 43 | 0 | 0 | 0 | 0 | 43 | 4.82 | 0.00 | 0.34 | 90\% |  | 8\% | 85\% | 89\% | 04/11/2016 |  |
| Morocco | 191 | 186 | 4 | 0 | 0 | 4 | 187 | 154 | 0 | 0 | 0 | 0 | 154 | 0.12 | 0.00 | 0.58 | 97\% | 97\% | 84\% | 100\% | 48\% | 25/12/2016 |  |
| Oman | 1844 | 1817 | 114 | 7 | 32 | 153 | 1691 | 1818 | 7 | 0 | 0 | 7 | 1811 | 34.66 | 1.59 | 38.15 | 99\% | 69\% | 74\% | 100\% | 100\% | 31/12/2016 | D8, D4, B3 |
| Pakistan | 5871 | 5871 | 2845 | 0 | 0 | 2845 | 3026 | 5871 | 645 | 0 | 0 | 645 | 5226 | 16.06 | 3.64 | 1.34 | 100\% |  | 68\% | 100\% | 74\% | 31/12/2016 | B3 |
| Palestine | 192 | 191 | 0 | 0 | 0 | 0 | 192 | 190 | 0 | 0 | 0 | 0 | 190 | 0.00 | 0.00 | 4.61 | 99\% | 99\% | 83\% | 100\% | 95\% | 25/12/2016 |  |
| Qatar | 251 | 246 | 27 | 3 | 0 | 30 | 221 | 171 | 20 | 0 | 0 | 20 | 151 | 17.31 | 11.54 | 11.60 | 99\% | 100\% | 100\% | 100\% | 86\% | 30/12/2016 |  |
| Saudi Arabia | 944 | 942 | 112 | 0 | 0 | 112 | 832 | 664 | 24 | 0 | 0 | 24 | 640 | 3.95 | 0.85 | 2.85 | 100\% | 96\% | 99\% | 100\% | 100\% | 30/12/2016 |  |
| Somalia | 35 | 35 | 29 | 0 | 0 | 29 | 6 | 8 | 0 | 0 | 0 | 0 | 8 | 3.33 | 0.00 | 0.07 | 100\% | 74\% | 94\% | 100\% | 57\% | 24/12/2016 |  |
| Sudan | 4533 | 3572 | 863 | 896 | 8 | 1767 | 2766 | 3571 | 935 | 60 | 1 | 996 | 2575 | 42.94 | 22.72 | 4.30 | 100\% | 100\% | 80\% | 98\% | 95\% | 31/12/2016 |  |
| Syria | 586 | 586 | 66 | 0 | 0 | 66 | 520 | 548 | 1 | 0 | 0 | 1 | 547 | 2.95 | 0.04 | 2.32 | 100\% | 97\% | 70\% | 97\% | 99\% | 31/12/2016 |  |
| Tunisia | 238 | 212 | 5 | 0 | 2 | 7 | 231 | 205 | 15 | 0 | 4 | 19 | 186 | 0.66 | 1.42 | 2.05 | 89\% | 28\% | 62\% | 100\% | 76\% | 25/12/2016 |  |
| UAE | 835 | 736 | 137 | 6 | 76 | 219 | 616 | 711 | 129 | 7 | 2 | 138 | 573 | 23.92 | 14.09 | 5.24 | 90\% | 91\% | 89\% | 100\% | 82\% | 31/12/2016 |  |
| Yemen | 3430 | 1173 | 97 | 46 | 0 | 143 | 3287 | 1408 | 54 | 2 | 0 | 56 | 1352 | 5.14 | 1.94 | 11.61 | 35\% | 96\% | 71\% | 100\% | 35\% | 18/12/2016 |  |
| Total EMR | 28225 | 24556 | 5201 | 1026 | 204 | 6431 | 21794 | 23680 | 1923 | 69 | 16 | 2008 | 21672 | 10.36 | 3.23 | 3.19 | 91\% | 76\% | 77\% | 99\% | 77\% |  |  |
| $* *$ The sum of the measles lab confirmed cases +measles epi-linked cases + measles clinically compatible Green cells= indicator met. <br> cases/million population <br> $* *$ The sum of the rubella lab confirmed cases +rubella epi-linked cases + rubella clinically compatible Adequate investigation includes the following data elements: <br> cases/million population <br> $* * * R e p o r t i n g ~ r a t e ~ o f ~ d i s c a r d e d ~ n o n-m e a s l e s ~ n o n-r u b e l l a ~ c a s e s ~ a t ~ t h e ~ n a t i o n a l ~ l e v e l ~ p e r ~ 100,000 ~ t o t a l ~ p o p u l a t i o n ~$   <br> -   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

## Countries that did not report

Djibouti

## Measles final classification and distribution by Month

Between 01/01/2016 and 31/12/2016

| Country | Total <br> Suspected <br> cases for <br> measles | Total <br> specimen <br> s tested | Measlesi <br> mported <br> cases | MeaslesI <br> mport <br> related* <br> $*$ | Vaccine <br> related <br> $* * *$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 1121 | 1120 | 0 | 0 | 0 |
| Bahrain | 398 | 398 | 3 | 13 | 7 |
| Iran | 4482 | 4374 | 0 | 0 | 157 |
| Iraq | 359 | 326 | 0 | 0 | 0 |
| Jordan | 36 | 36 | 4 | 0 | 10 |
| Egypt | 2528 | 2424 | 0 | 0 | 4 |
| Kuwait | 176 | 174 | 0 | 0 | 4 |
| Lebanon | 127 | 94 | 0 | 0 | 0 |
| Libya | 191 | 4843 | 0 | 0 | 0 |
| Morocco | 5871 | 5871 | 0 | 0 | 0 |
| Oman | 192 | 191 | 0 | 0 | 0 |
| Pakistan | 251 | 246 | 0 | 0 | 15 |
| Palestine | 944 | 942 | 0 | 0 | 10 |
| Qatar | 35 | 35 | 0 | 0 | 0 |
| Saudi Arabia | 4533 | 3572 | 0 | 0 | 0 |
| Somalia | 586 | 586 | 0 | 0 | 34 |
| Sudan | 238 | 212 | 0 | 0 | 0 |
| Syria | 835 | 736 | 0 | 0 | 0 |
| Tunisia | 3430 | 1173 | 0 | 0 | 0 |
| UAE | 28225 | 24556 | 7 | 13 | 316 |
| Yemen |  | 0 | 0 | 70 |  |
| Total | 1817 |  |  |  |  |
|  |  | 0 | 0 |  |  |


| Measles lab confirme d | Measles EpiLinked | Measles clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 641 | 0 | 0 | 641 | 8 | 62 | 52 | 79 | 66 | 99 | 40 | 26 | 22 | 35 | 35 | 117 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 63 | 8 | 12 | 83 | 5 | 10 | 4 | 3 | 5 | 1 | 3 | 2 | 1 | 3 | 9 | 37 |
| 27 | 0 | 0 | 27 | 4 | 2 | 2 | 1 | 3 | 4 | 3 | 5 | 2 | 0 | 1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 122 | 60 | 43 | 225 | 31 | 13 | 35 | 57 | 25 | 23 | 20 | 12 | 2 | 4 | 1 | 2 |
| 8 | 0 | 0 | 8 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| 13 | 0 | 31 | 44 | 2 | 0 | 6 | 4 | 9 | 6 | 3 | 6 | 3 | 3 | 1 | 1 |
| 28 | 0 | 0 | 28 | 0 | 0 | 0 | 4 | 17 | 5 | 0 | 0 | 0 | 2 | 0 | 0 |
| 4 | 0 | 0 | 4 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 114 | 7 | 32 | 153 | 4 | 5 | 5 | 5 | 12 | 4 | 7 | 7 | 22 | 31 | 30 | 21 |
| 2845 | 0 | 0 | 2845 | 104 | 151 | 301 | 453 | 470 | 194 | 122 | 138 | 128 | 188 | 193 | 403 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | 3 | 0 | 30 | 2 | 1 | 1 | 11 | 5 | 0 | 0 | 2 | 1 | 2 | 3 | 2 |
| 112 | 0 | 0 | 112 | 6 | 8 | 8 | 0 | 7 | 4 | 18 | 19 | 7 | 12 | 8 | 15 |
| 29 | 0 | 0 | 29 | 2 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 4 | 7 |
| 863 | 896 | 8 | 1767 | 82 | 178 | 481 | 330 | 295 | 99 | 69 | 58 | 37 | 40 | 48 | 50 |
| 66 | 0 | 0 | 66 | 0 | 1 | 2 | 4 | 12 | 5 | 9 | 3 | 0 | 4 | 9 | 17 |
| 5 | 0 | 2 | 7 | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| 137 | 6 | 76 | 219 | 22 | 23 | 29 | 33 | 30 | 16 | 15 | 14 | 10 | 8 | 15 | 4 |
| 97 | 46 | 0 | 143 | 23 | 25 | 36 | 0 | 0 | 4 | 14 | 2 | 0 | 17 | 22 | 0 |
| 5201 | 1026 | 204 | 6431 | 299 | 481 | 969 | 989 | 958 | 465 | 323 | 295 | 236 | 361 | 379 | 676 |

[^0]Cumulative geographic distribution of Measles cases in the EMR countries year 2016


## Rubella final classification and distribution by Month

Between 01/01/2016 and 31/12/2016

| Country | Total <br> Suspected <br> cases for <br> rubella | Total <br> specimen <br> s tested | Rubella <br> importe <br> $\mathbf{d}^{*}$ | Rubellai <br> mport <br> related <br> $* *$ | Rubella <br> vaccine <br> related* <br> $* *$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 1121 | 485 | 0 | 0 | 0 |
| Bahrain | 398 | 398 | 1 | 0 | 7 |
| Iran | 4482 | 4374 | 0 | 0 | 157 |
| Iraq | 359 | 346 | 0 | 0 | 0 |
| Jordan | 36 | 36 | 0 | 0 | 10 |
| Egypt | 2528 | 2422 | 0 | 0 | 4 |
| Kuwait | 176 | 174 | 0 | 0 | 4 |
| Lebanon | 487 | 83 | 0 | 0 | 0 |
| Libya | 191 | 43 | 0 | 0 | 0 |
| Morocco | 5871 | 154 | 0 | 0 | 0 |
| Oman | 192 | 1818 | 0 | 0 | 70 |
| Pakistan | 251 | 171 | 0 | 0 | 15 |
| Palestine | 944 | 664 | 0 | 0 | 10 |
| Qatar | 35 | 8 | 0 | 0 | 0 |
| Saudi Arabia | 4533 | 3571 | 0 | 0 | 0 |
| Somalia | 586 | 548 | 0 | 0 | 34 |
| Sudan | 238 | 205 | 0 | 0 | 0 |
| Syria | 835 | 711 | 0 | 0 | 0 |
| Tunisia | 3430 | 1408 | 0 | 0 | 0 |
| UAE | $\mathbf{2 8 2 2 5}$ | 23680 | $\mathbf{1}$ | 0 | 316 |
| Yemen |  |  | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |  |  |
|  |  | 0 | 0 | 0 |  |


| Rubella lab confirme d | Rubella EpiLinked | Rubella clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 42 | 0 | 0 | 42 | 1 | 6 | 5 | 7 | 6 | 7 | 1 | 0 | 1 | 2 | 1 | 5 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | 0 | 3 | 18 | 3 | 1 | 3 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 3 | 2 |
| 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | 0 | 0 | 28 | 5 | 0 | 1 | 6 | 0 | 1 | 3 | 4 | 1 | 4 | 2 | 1 |
| 3 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| 4 | 0 | 6 | 10 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 4 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 7 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| 645 | 0 | 0 | 645 | 8 | 68 | 144 | 183 | 185 | 37 | 10 | 1 | 3 | 0 | 1 | 5 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 20 | 0 | 0 | 20 | 0 | 1 | 0 | 3 | 8 | 3 | 2 | 2 | 1 | 0 | 0 | 0 |
| 24 | 0 | 0 | 24 | 0 | 0 | 0 | 0 | 2 | 0 | 5 | 6 | 4 | 1 | 2 | 4 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 935 | 60 | 1 | 996 | 163 | 348 | 173 | 93 | 68 | 46 | 17 | 8 | 8 | 24 | 22 | 26 |
| 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | 0 | 4 | 19 | 1 | 3 | 1 | 2 | 2 | 2 | 1 | 0 | 1 | 4 | 2 | 0 |
| 129 | 7 | 2 | 138 | 2 | 10 | 12 | 30 | 28 | 23 | 8 | 4 | 9 | 4 | 4 | 4 |
| 54 | 2 | 0 | 56 | 8 | 19 | 8 | 5 | 0 | 2 | 11 | 3 | 0 | 0 | 0 | 0 |
| 1923 | 69 | 16 | 2008 | 193 | 457 | 347 | 333 | 302 | 122 | 61 | 29 | 29 | 43 | 41 | 51 |

[^1]
## Cumulative geographic distribution of Rubella cases in the EMR countries year 2016



Measles and Rubella laboratory summary report
Between 01/01/2016 and 31/12/2016

| Country | Total Suspected cases M/R | Measles |  |  |  |  |  |  |  | Rubella |  |  |  |  |  |  |  | Reporte d to EPI within 4days |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% |  |
| Afghanistan | 1121 | 1120 | 100\% | 641 | 57\% | 479 | 43\% | 0 | 0\% | 485 | 43\% | 51 | 11\% | 434 | 89\% | 0 | 0\% | 40\% |
| Bahrain | 398 | 398 | 100\% | 20 | 5\% | 373 | 94\% | 5 | 1\% | 398 | 100\% | 4 | 1\% | 393 | 99\% | 1 | 0\% | 99\% |
| Iran | 4482 | 4374 | 98\% | 167 | 4\% | 4206 | 96\% | 1 | 0\% | 4374 | 98\% | 103 | 2\% | 4270 | 98\% | 1 | 0\% | 96\% |
| Iraq | 359 | 326 | 91\% | 27 | 8\% | 299 | 92\% | 0 | 0\% | 346 | 96\% | 1 | 0\% | 345 | 100\% | 0 | 0\% | 89\% |
| Jordan | 36 | 36 | 100\% | 10 | 28\% | 24 | 67\% | 2 | 6\% | 36 | 100\% | 2 | 6\% | 34 | 94\% | 0 | 0\% | 58\% |
| Egypt | 2528 | 2424 | 96\% | 125 | 5\% | 2299 | 95\% | 0 | 0\% | 2422 | 96\% | 32 | 1\% | 2390 | 99\% | 0 | 0\% | 93\% |
| Kuwait | 176 | 174 | 99\% | 12 | 7\% | 162 | 93\% | 0 | 0\% | 174 | 99\% | 3 | 2\% | 171 | 98\% | 0 | 0\% | 9\% |
| Lebanon | 127 | 94 | 74\% | 13 | 14\% | 81 | 86\% | 0 | 0\% | 83 | 65\% | 4 | 5\% | 75 | 90\% | 4 | 5\% | 96\% |
| Libya | 48 | 43 | 90\% | 28 | 65\% | 13 | 30\% | 2 | 5\% | 43 | 90\% | 0 | 0\% | 43 | 100\% | 0 | 0\% | 89\% |
| Morocco | 191 | 186 | 97\% | 4 | 2\% | 180 | 97\% | 2 | 1\% | 154 | 81\% | 0 | 0\% | 153 | 99\% | 1 | 1\% | 48\% |
| Oman | 1844 | 1817 | 99\% | 144 | 8\% | 1637 | 90\% | 36 | 2\% | 1818 | 99\% | 40 | 2\% | 1764 | 97\% | 14 | 1\% | 100\% |
| Pakistan | 5871 | 5871 | 100\% | 2845 | 48\% | 3026 | 52\% | 0 | 0\% | 5871 | 100\% | 645 | 11\% | 5226 | 89\% | 0 | 0\% | 74\% |
| Palestine | 192 | 191 | 99\% | 5 | 3\% | 186 | 97\% | 0 | 0\% | 190 | 99\% | 4 | 2\% | 183 | 96\% | 3 | 2\% | 95\% |
| Qatar | 251 | 246 | 98\% | 40 | 16\% | 206 | 84\% | 0 | 0\% | 171 | 68\% | 19 | 11\% | 147 | 86\% | 5 | 3\% | 86\% |
| Saudi Arabia | 944 | 942 | 100\% | 120 | 13\% | 822 | 87\% | 0 | 0\% | 664 | 70\% | 31 | 5\% | 633 | 95\% | 0 | 0\% | 100\% |
| Somalia | 35 | 35 | 100\% | 29 | 83\% | 6 | 17\% | 0 | 0\% | 8 | 23\% | 0 | 0\% | 8 | 100\% | 0 | 0\% | 57\% |
| Sudan | 4533 | 3572 | 79\% | 863 | 24\% | 2708 | 76\% | 1 | 0\% | 3571 | 79\% | 1023 | 29\% | 2548 | 71\% | 0 | 0\% | 95\% |
| Syria | 586 | 586 | 100\% | 86 | 15\% | 489 | 83\% | 11 | 2\% | 548 | 94\% | 19 | 3\% | 523 | 95\% | 6 | 1\% | 99\% |
| Tunisia | 238 | 212 | 89\% | 8 | 4\% | 204 | 96\% | 0 | 0\% | 205 | 86\% | 19 | 9\% | 186 | 91\% | 0 | 0\% | 76\% |
| UAE | 835 | 736 | 88\% | 138 | 19\% | 572 | 78\% | 26 | 4\% | 711 | 85\% | 133 | 19\% | 574 | 81\% | 4 | 1\% | 82\% |
| Yemen | 3430 | 1173 | 34\% | 70 | 6\% | 1074 | 92\% | 29 | 2\% | 1408 | 41\% | 22 | 2\% | 1352 | 96\% | 34 | 2\% | 35\% |
| Total | 28225 | 24556 | 87\% | 5395 | 22\% | 19046 | 78\% | 115 | 0\% | 23680 | 84\% | 2155 | 9\% | 21452 | 91\% | 73 | 0\% | 77\% |


[^0]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

[^1]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

